aluates Reports

$ 0.0

Automative

Global Bi-Specific MAbS Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-0U10473

Global Bi Specific MAbS Market Insights Forecast to 2028

BUY CHAPTERS

Global Bi-Specific MAbS Market Research Report 2025

Code: QYRE-Auto-0U10473

Report

July 2025

Pages:94

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Johnson and Johnson

Novartis

Hoffmann-La Roche Ltd

Chugai Pharmaceutical

Bayer

Thermo Fisher Scientific

Mylan N.V.

Daiichi Sankyo Company

Abbott

Astrazeneca plc

Eli Lilly

Merck and Co.

Amgen Inc

Pfizer Inc

GlaxoSmithKline PLC

Roche

Bistro-Myers Squibb

Bi-Specific MAbS Market

The global market for Bi-Specific MAbS was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.

North American market for Bi-Specific MAbS is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Bi-Specific MAbS is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Bi-Specific MAbS in Cancer is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Bi-Specific MAbS include Johnson and Johnson, Novartis AG, Hoffmann-La Roche Ltd., Chugai Pharmaceutical, Bayer AG, Thermo Fisher Scientific, Bistro-Myers Squibb, Mylan N.V., Daiichi Sankyo Company, Abbott, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Bi-Specific MAbS, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific MAbS.

The Bi-Specific MAbS market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Bi-Specific MAbS market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Bi-Specific MAbS companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Bi-Specific MAbS Market Report

Report Metric	Details
Report Name	Bi-Specific MAbS Market
Segment by Type	Catumaxomab Blinatumomab Duligotumab SAR 156597
Segment by Application	Cancer Autoimmune Diseases Inflammatory Diseases Infectious Diseases Microbial Diseases Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Johnson and Johnson, Novartis AG, Hoffmann-La Roche Ltd., Chugai Pharmaceutical, Bayer AG, Thermo Fisher Scientific, Bistro-Myers Squibb, Mylan N.V., Daiichi Sankyo Company, Abbott, AstraZeneca, Eli Lilly, Merck and Co., Amgen, Pfizer, GlaxoSmithKline plc, Roche
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bi-Specific MAbS company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Bi-Specific MAbS Market report?

Ans: The main players in the Bi-Specific MAbS Market are Johnson and Johnson, Novartis AG, Hoffmann-La Roche Ltd., Chugai Pharmaceutical, Bayer AG, Thermo Fisher Scientific, Bistro-Myers Squibb, Mylan N.V., Daiichi Sankyo Company, Abbott, AstraZeneca, Eli Lilly, Merck and Co., Amgen, Pfizer, GlaxoSmithKline plc, Roche

What are the Application segmentation covered in the Bi-Specific MAbS Market report?

Ans: The Applications covered in the Bi-Specific MAbS Market report are Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Others

What are the Type segmentation covered in the Bi-Specific MAbS Market report?

Ans: The Types covered in the Bi-Specific MAbS Market report are Catumaxomab, Blinatumomab, Duligotumab, SAR 156597

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Bi-Specific MAbS Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Catumaxomab

1.2.3 Blinatumomab

1.2.4 Duligotumab

1.2.5 SAR 156597

1.3 Market by Application

1.3.1 Global Bi-Specific MAbS Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Cancer

1.3.3 Autoimmune Diseases

1.3.4 Inflammatory Diseases

1.3.5 Infectious Diseases

1.3.6 Microbial Diseases

1.3.7 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Bi-Specific MAbS Market Perspective (2020-2031)

2.2 Global Bi-Specific MAbS Growth Trends by Region

2.2.1 Global Bi-Specific MAbS Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Bi-Specific MAbS Historic Market Size by Region (2020-2025)

2.2.3 Bi-Specific MAbS Forecasted Market Size by Region (2026-2031)

2.3 Bi-Specific MAbS Market Dynamics

2.3.1 Bi-Specific MAbS Industry Trends

2.3.2 Bi-Specific MAbS Market Drivers

2.3.3 Bi-Specific MAbS Market Challenges

2.3.4 Bi-Specific MAbS Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Bi-Specific MAbS Players by Revenue

3.1.1 Global Top Bi-Specific MAbS Players by Revenue (2020-2025)

3.1.2 Global Bi-Specific MAbS Revenue Market Share by Players (2020-2025)

3.2 Global Bi-Specific MAbS Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Bi-Specific MAbS Revenue

3.4 Global Bi-Specific MAbS Market Concentration Ratio

3.4.1 Global Bi-Specific MAbS Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Bi-Specific MAbS Revenue in 2024

3.5 Global Key Players of Bi-Specific MAbS Head office and Area Served

3.6 Global Key Players of Bi-Specific MAbS, Product and Application

3.7 Global Key Players of Bi-Specific MAbS, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Bi-Specific MAbS Breakdown Data by Type

4.1 Global Bi-Specific MAbS Historic Market Size by Type (2020-2025)

4.2 Global Bi-Specific MAbS Forecasted Market Size by Type (2026-2031)

5 Bi-Specific MAbS Breakdown Data by Application

5.1 Global Bi-Specific MAbS Historic Market Size by Application (2020-2025)

5.2 Global Bi-Specific MAbS Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Bi-Specific MAbS Market Size (2020-2031)

6.2 North America Bi-Specific MAbS Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Bi-Specific MAbS Market Size by Country (2020-2025)

6.4 North America Bi-Specific MAbS Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Bi-Specific MAbS Market Size (2020-2031)

7.2 Europe Bi-Specific MAbS Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Bi-Specific MAbS Market Size by Country (2020-2025)

7.4 Europe Bi-Specific MAbS Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Bi-Specific MAbS Market Size (2020-2031)

8.2 Asia-Pacific Bi-Specific MAbS Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Bi-Specific MAbS Market Size by Region (2020-2025)

8.4 Asia-Pacific Bi-Specific MAbS Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Bi-Specific MAbS Market Size (2020-2031)

9.2 Latin America Bi-Specific MAbS Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Bi-Specific MAbS Market Size by Country (2020-2025)

9.4 Latin America Bi-Specific MAbS Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Bi-Specific MAbS Market Size (2020-2031)

10.2 Middle East & Africa Bi-Specific MAbS Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Bi-Specific MAbS Market Size by Country (2020-2025)

10.4 Middle East & Africa Bi-Specific MAbS Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Johnson and Johnson

11.1.1 Johnson and Johnson Company Details

11.1.2 Johnson and Johnson Business Overview

11.1.3 Johnson and Johnson Bi-Specific MAbS Introduction

11.1.4 Johnson and Johnson Revenue in Bi-Specific MAbS Business (2020-2025)

11.1.5 Johnson and Johnson Recent Development

11.2 Novartis AG

11.2.1 Novartis AG Company Details

11.2.2 Novartis AG Business Overview

11.2.3 Novartis AG Bi-Specific MAbS Introduction

11.2.4 Novartis AG Revenue in Bi-Specific MAbS Business (2020-2025)

11.2.5 Novartis AG Recent Development

11.3 Hoffmann-La Roche Ltd.

11.3.1 Hoffmann-La Roche Ltd. Company Details

11.3.2 Hoffmann-La Roche Ltd. Business Overview

11.3.3 Hoffmann-La Roche Ltd. Bi-Specific MAbS Introduction

11.3.4 Hoffmann-La Roche Ltd. Revenue in Bi-Specific MAbS Business (2020-2025)

11.3.5 Hoffmann-La Roche Ltd. Recent Development

11.4 Chugai Pharmaceutical

11.4.1 Chugai Pharmaceutical Company Details

11.4.2 Chugai Pharmaceutical Business Overview

11.4.3 Chugai Pharmaceutical Bi-Specific MAbS Introduction

11.4.4 Chugai Pharmaceutical Revenue in Bi-Specific MAbS Business (2020-2025)

11.4.5 Chugai Pharmaceutical Recent Development

11.5 Bayer AG

11.5.1 Bayer AG Company Details

11.5.2 Bayer AG Business Overview

11.5.3 Bayer AG Bi-Specific MAbS Introduction

11.5.4 Bayer AG Revenue in Bi-Specific MAbS Business (2020-2025)

11.5.5 Bayer AG Recent Development

11.6 Thermo Fisher Scientific

11.6.1 Thermo Fisher Scientific Company Details

11.6.2 Thermo Fisher Scientific Business Overview

11.6.3 Thermo Fisher Scientific Bi-Specific MAbS Introduction

11.6.4 Thermo Fisher Scientific Revenue in Bi-Specific MAbS Business (2020-2025)

11.6.5 Thermo Fisher Scientific Recent Development

11.7 Bistro-Myers Squibb

11.7.1 Bistro-Myers Squibb Company Details

11.7.2 Bistro-Myers Squibb Business Overview

11.7.3 Bistro-Myers Squibb Bi-Specific MAbS Introduction

11.7.4 Bistro-Myers Squibb Revenue in Bi-Specific MAbS Business (2020-2025)

11.7.5 Bistro-Myers Squibb Recent Development

11.8 Mylan N.V.

11.8.1 Mylan N.V. Company Details

11.8.2 Mylan N.V. Business Overview

11.8.3 Mylan N.V. Bi-Specific MAbS Introduction

11.8.4 Mylan N.V. Revenue in Bi-Specific MAbS Business (2020-2025)

11.8.5 Mylan N.V. Recent Development

11.9 Daiichi Sankyo Company

11.9.1 Daiichi Sankyo Company Company Details

11.9.2 Daiichi Sankyo Company Business Overview

11.9.3 Daiichi Sankyo Company Bi-Specific MAbS Introduction

11.9.4 Daiichi Sankyo Company Revenue in Bi-Specific MAbS Business (2020-2025)

11.9.5 Daiichi Sankyo Company Recent Development

11.10 Abbott

11.10.1 Abbott Company Details

11.10.2 Abbott Business Overview

11.10.3 Abbott Bi-Specific MAbS Introduction

11.10.4 Abbott Revenue in Bi-Specific MAbS Business (2020-2025)

11.10.5 Abbott Recent Development

11.11 AstraZeneca

11.11.1 AstraZeneca Company Details

11.11.2 AstraZeneca Business Overview

11.11.3 AstraZeneca Bi-Specific MAbS Introduction

11.11.4 AstraZeneca Revenue in Bi-Specific MAbS Business (2020-2025)

11.11.5 AstraZeneca Recent Development

11.12 Eli Lilly

11.12.1 Eli Lilly Company Details

11.12.2 Eli Lilly Business Overview

11.12.3 Eli Lilly Bi-Specific MAbS Introduction

11.12.4 Eli Lilly Revenue in Bi-Specific MAbS Business (2020-2025)

11.12.5 Eli Lilly Recent Development

11.13 Merck and Co.

11.13.1 Merck and Co. Company Details

11.13.2 Merck and Co. Business Overview

11.13.3 Merck and Co. Bi-Specific MAbS Introduction

11.13.4 Merck and Co. Revenue in Bi-Specific MAbS Business (2020-2025)

11.13.5 Merck and Co. Recent Development

11.14 Amgen

11.14.1 Amgen Company Details

11.14.2 Amgen Business Overview

11.14.3 Amgen Bi-Specific MAbS Introduction

11.14.4 Amgen Revenue in Bi-Specific MAbS Business (2020-2025)

11.14.5 Amgen Recent Development

11.15 Pfizer

11.15.1 Pfizer Company Details

11.15.2 Pfizer Business Overview

11.15.3 Pfizer Bi-Specific MAbS Introduction

11.15.4 Pfizer Revenue in Bi-Specific MAbS Business (2020-2025)

11.15.5 Pfizer Recent Development

11.16 GlaxoSmithKline plc

11.16.1 GlaxoSmithKline plc Company Details

11.16.2 GlaxoSmithKline plc Business Overview

11.16.3 GlaxoSmithKline plc Bi-Specific MAbS Introduction

11.16.4 GlaxoSmithKline plc Revenue in Bi-Specific MAbS Business (2020-2025)

11.16.5 GlaxoSmithKline plc Recent Development

11.17 Roche

11.17.1 Roche Company Details

11.17.2 Roche Business Overview

11.17.3 Roche Bi-Specific MAbS Introduction

11.17.4 Roche Revenue in Bi-Specific MAbS Business (2020-2025)

11.17.5 Roche Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Johnson and Johnson

Novartis

Hoffmann-La Roche Ltd

Chugai Pharmaceutical

Bayer

Thermo Fisher Scientific

Mylan N.V.

Daiichi Sankyo Company

Abbott

Astrazeneca plc

Eli Lilly

Merck and Co.

Amgen Inc

Pfizer Inc

GlaxoSmithKline PLC

Roche

Bistro-Myers Squibb

List of Tables

Table 1. Global Bi-Specific MAbS Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Catumaxomab

Table 3. Key Players of Blinatumomab

Table 4. Key Players of Duligotumab

Table 5. Key Players of SAR 156597

Table 6. Global Bi-Specific MAbS Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Bi-Specific MAbS Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Bi-Specific MAbS Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Bi-Specific MAbS Market Share by Region (2020-2025)

Table 10. Global Bi-Specific MAbS Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Bi-Specific MAbS Market Share by Region (2026-2031)

Table 12. Bi-Specific MAbS Market Trends

Table 13. Bi-Specific MAbS Market Drivers

Table 14. Bi-Specific MAbS Market Challenges

Table 15. Bi-Specific MAbS Market Restraints

Table 16. Global Bi-Specific MAbS Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Bi-Specific MAbS Market Share by Players (2020-2025)

Table 18. Global Top Bi-Specific MAbS Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific MAbS as of 2024)

Table 19. Ranking of Global Top Bi-Specific MAbS Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Bi-Specific MAbS Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Bi-Specific MAbS, Headquarters and Area Served

Table 22. Global Key Players of Bi-Specific MAbS, Product and Application

Table 23. Global Key Players of Bi-Specific MAbS, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Bi-Specific MAbS Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Bi-Specific MAbS Revenue Market Share by Type (2020-2025)

Table 27. Global Bi-Specific MAbS Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Bi-Specific MAbS Revenue Market Share by Type (2026-2031)

Table 29. Global Bi-Specific MAbS Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Bi-Specific MAbS Revenue Market Share by Application (2020-2025)

Table 31. Global Bi-Specific MAbS Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Bi-Specific MAbS Revenue Market Share by Application (2026-2031)

Table 33. North America Bi-Specific MAbS Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Bi-Specific MAbS Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Bi-Specific MAbS Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Bi-Specific MAbS Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Bi-Specific MAbS Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Bi-Specific MAbS Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Bi-Specific MAbS Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Bi-Specific MAbS Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Bi-Specific MAbS Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Bi-Specific MAbS Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Bi-Specific MAbS Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Bi-Specific MAbS Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Bi-Specific MAbS Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Bi-Specific MAbS Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Bi-Specific MAbS Market Size by Country (2026-2031) & (US$ Million)

Table 48. Johnson and Johnson Company Details

Table 49. Johnson and Johnson Business Overview

Table 50. Johnson and Johnson Bi-Specific MAbS Product

Table 51. Johnson and Johnson Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 52. Johnson and Johnson Recent Development

Table 53. Novartis AG Company Details

Table 54. Novartis AG Business Overview

Table 55. Novartis AG Bi-Specific MAbS Product

Table 56. Novartis AG Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 57. Novartis AG Recent Development

Table 58. Hoffmann-La Roche Ltd. Company Details

Table 59. Hoffmann-La Roche Ltd. Business Overview

Table 60. Hoffmann-La Roche Ltd. Bi-Specific MAbS Product

Table 61. Hoffmann-La Roche Ltd. Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 62. Hoffmann-La Roche Ltd. Recent Development

Table 63. Chugai Pharmaceutical Company Details

Table 64. Chugai Pharmaceutical Business Overview

Table 65. Chugai Pharmaceutical Bi-Specific MAbS Product

Table 66. Chugai Pharmaceutical Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 67. Chugai Pharmaceutical Recent Development

Table 68. Bayer AG Company Details

Table 69. Bayer AG Business Overview

Table 70. Bayer AG Bi-Specific MAbS Product

Table 71. Bayer AG Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 72. Bayer AG Recent Development

Table 73. Thermo Fisher Scientific Company Details

Table 74. Thermo Fisher Scientific Business Overview

Table 75. Thermo Fisher Scientific Bi-Specific MAbS Product

Table 76. Thermo Fisher Scientific Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 77. Thermo Fisher Scientific Recent Development

Table 78. Bistro-Myers Squibb Company Details

Table 79. Bistro-Myers Squibb Business Overview

Table 80. Bistro-Myers Squibb Bi-Specific MAbS Product

Table 81. Bistro-Myers Squibb Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 82. Bistro-Myers Squibb Recent Development

Table 83. Mylan N.V. Company Details

Table 84. Mylan N.V. Business Overview

Table 85. Mylan N.V. Bi-Specific MAbS Product

Table 86. Mylan N.V. Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 87. Mylan N.V. Recent Development

Table 88. Daiichi Sankyo Company Company Details

Table 89. Daiichi Sankyo Company Business Overview

Table 90. Daiichi Sankyo Company Bi-Specific MAbS Product

Table 91. Daiichi Sankyo Company Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 92. Daiichi Sankyo Company Recent Development

Table 93. Abbott Company Details

Table 94. Abbott Business Overview

Table 95. Abbott Bi-Specific MAbS Product

Table 96. Abbott Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 97. Abbott Recent Development

Table 98. AstraZeneca Company Details

Table 99. AstraZeneca Business Overview

Table 100. AstraZeneca Bi-Specific MAbS Product

Table 101. AstraZeneca Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 102. AstraZeneca Recent Development

Table 103. Eli Lilly Company Details

Table 104. Eli Lilly Business Overview

Table 105. Eli Lilly Bi-Specific MAbS Product

Table 106. Eli Lilly Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 107. Eli Lilly Recent Development

Table 108. Merck and Co. Company Details

Table 109. Merck and Co. Business Overview

Table 110. Merck and Co. Bi-Specific MAbS Product

Table 111. Merck and Co. Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 112. Merck and Co. Recent Development

Table 113. Amgen Company Details

Table 114. Amgen Business Overview

Table 115. Amgen Bi-Specific MAbS Product

Table 116. Amgen Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 117. Amgen Recent Development

Table 118. Pfizer Company Details

Table 119. Pfizer Business Overview

Table 120. Pfizer Bi-Specific MAbS Product

Table 121. Pfizer Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 122. Pfizer Recent Development

Table 123. GlaxoSmithKline plc Company Details

Table 124. GlaxoSmithKline plc Business Overview

Table 125. GlaxoSmithKline plc Bi-Specific MAbS Product

Table 126. GlaxoSmithKline plc Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 127. GlaxoSmithKline plc Recent Development

Table 128. Roche Company Details

Table 129. Roche Business Overview

Table 130. Roche Bi-Specific MAbS Product

Table 131. Roche Revenue in Bi-Specific MAbS Business (2020-2025) & (US$ Million)

Table 132. Roche Recent Development

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Bi-Specific MAbS Picture

Figure 2. Global Bi-Specific MAbS Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Bi-Specific MAbS Market Share by Type: 2024 VS 2031

Figure 4. Catumaxomab Features

Figure 5. Blinatumomab Features

Figure 6. Duligotumab Features

Figure 7. SAR 156597 Features

Figure 8. Global Bi-Specific MAbS Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Bi-Specific MAbS Market Share by Application: 2024 VS 2031

Figure 10. Cancer Case Studies

Figure 11. Autoimmune Diseases Case Studies

Figure 12. Inflammatory Diseases Case Studies

Figure 13. Infectious Diseases Case Studies

Figure 14. Microbial Diseases Case Studies

Figure 15. Others Case Studies

Figure 16. Bi-Specific MAbS Report Years Considered

Figure 17. Global Bi-Specific MAbS Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 18. Global Bi-Specific MAbS Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 19. Global Bi-Specific MAbS Market Share by Region: 2024 VS 2031

Figure 20. Global Bi-Specific MAbS Market Share by Players in 2024

Figure 21. Global Top Bi-Specific MAbS Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific MAbS as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by Bi-Specific MAbS Revenue in 2024

Figure 23. North America Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. North America Bi-Specific MAbS Market Share by Country (2020-2031)

Figure 25. United States Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Canada Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Bi-Specific MAbS Market Share by Country (2020-2031)

Figure 29. Germany Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Bi-Specific MAbS Market Share by Region (2020-2031)

Figure 37. China Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Japan Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. South Korea Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. India Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Australia Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Bi-Specific MAbS Market Share by Country (2020-2031)

Figure 45. Mexico Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Brazil Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Bi-Specific MAbS Market Share by Country (2020-2031)

Figure 49. Turkey Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. UAE Bi-Specific MAbS Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Johnson and Johnson Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 53. Novartis AG Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 54. Hoffmann-La Roche Ltd. Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 55. Chugai Pharmaceutical Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 56. Bayer AG Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 57. Thermo Fisher Scientific Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 58. Bistro-Myers Squibb Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 59. Mylan N.V. Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 60. Daiichi Sankyo Company Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 61. Abbott Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 62. AstraZeneca Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 63. Eli Lilly Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 64. Merck and Co. Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 65. Amgen Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 66. Pfizer Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 67. GlaxoSmithKline plc Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 68. Roche Revenue Growth Rate in Bi-Specific MAbS Business (2020-2025)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Bispecific Antibodies for Cancer Market Insights Forecast to 2030

Global T Cell NK Cell Engaging Bispecific Antibodies Market Research Report 2025

Global Bispecific Antibody Molecular Drug Market Research Report 2025

Global Bispecific Antibody Development Platform Market Research Report 2024

Global Bi Specific Antibodies Therapy Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030

Bi Specific Antibodies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Bispecific Monoclonal Antibodies Market Research Report 2024

Global Bispecific Antibody Therapeutic Market Insights Forecast to 2030

Bispecific Antibody Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Bispecific Antibody Technology Platform Market Research Report 2025

Global CD Targeted Bispecific Antibody Market Research Report 2024

BiSpecific MAbS Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Humanized Bispecific Antibody Market Research Report 2024

Bispecific Antibodies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Bispecific and Trispecific Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Humanized Bispecific Antibodies Market Research Report 2024

Global Therapeutic Monoclonal Antibodies Market Research Report 2024

Global Therapeutic Monoclonal Antibodies Drug Market Research Report 2024

Global BCMA CD3 Bispecific Antibody Market Research Report 2024

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions